MAPT and Alzheimer disease: Advanced models using deep learning algorithms should consider DBSI-RF in the prediction of cognitive decline in AD as part of a multimodal assessment, including neuropsychological tests, imaging data, and peripheral plasma biomarkers (e.g., Aβ42/β40, phosphorylated tau, and neurofilament light) [44].